This intellectual property will affect the Quick-Med Technologies in a great way, as the Rosacea disease is prevalent in nearly 16 million American, so a very effective technique of curing Rosacea will gives them a huge market and big profits because other treatments available have side effects and other companies can’t use this technique due to intellectual property rights of Quick-Med Technologies. Competing companies would be affected by this intellectual property of Quick-Med Technologies, as they can’t use this more effective technique and the current techniques have side effects so they are likely to face low sales of their products which are associated with the treatment of Rosacea.
Advanced Cell Technology, Inc has many Intellectual properties in the area of regenerative medicine. They have utility patents like methods for treating retinal degeneration using human RPE cells and manufacturing RPE cells from human ES cells.
Advanced Cell Technologies has acquired these patents because this is potentially a very large market, there are some 200 or more diseases of retina which effects millions of people worldwide, and that may be treated by using their technology of RPE cells. Secondly there are currently no available treatments for some diseases like Stargardts Disease and Age related Macular Degeneration, which can be treated with their new treatment technology, and which is potentially a 20-30 billion dollar market.
These new intellectual properties will extend the companys patent coverage of the scalable manufacturing of human RPE cells for therapeutic use, this Intellectual property will further expands their patent estate with respect to protecting the use of RPE cells in a wide range of treatments. As this is a multibillion dollar market and there are currently no available cures for some of the diseases